Springworks Therapeutics Stock Today
| SWTX Stock | USD 49.89 1.19 2.33% |
PerformanceOK
| Odds Of DistressBelow Average
|
SpringWorks Therapeutics is trading at 49.89 as of the 23rd of March 2025; that is 2.33 percent decrease since the beginning of the trading day. The stock's open price was 51.08. SpringWorks Therapeutics has about a 41 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Note, on February 12, 2025, Representative Gil Cisneros of US Congress acquired under $15k worth of SpringWorks Therapeutics's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of June 1987 | Category Healthcare | Classification Health Care |
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. The company has 74.94 M outstanding shares of which 9.11 M shares are at this time shorted by private and institutional investors with about 2.19 trading days to cover. More on SpringWorks Therapeutics
Moving against SpringWorks Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
SpringWorks Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsSpringWorks Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand SpringWorks Therapeutics' financial leverage. It provides some insight into what part of SpringWorks Therapeutics' total assets is financed by creditors.
| |||||
SpringWorks Therapeutics (SWTX) is traded on NASDAQ Exchange in USA. It is located in 100 Washington Boulevard, Stamford, CT, United States, 06902 and employs 368 people. SpringWorks Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.74 B. SpringWorks Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 74.94 M outstanding shares of which 9.11 M shares are at this time shorted by private and institutional investors with about 2.19 trading days to cover.
SpringWorks Therapeutics currently holds about 334.54 M in cash with (175.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.81.
Check SpringWorks Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of SpringWorks Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in SpringWorks Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in SpringWorks Therapeutics. Please pay attention to any change in the institutional holdings of SpringWorks Therapeutics as this could imply that something significant has changed or is about to change at the company. On February 12, 2025, Representative Gil Cisneros of US Congress acquired under $15k worth of SpringWorks Therapeutics's common stock.
Check SpringWorks Ownership Details
SpringWorks Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1.7 M | |
| Ecor1 Capital, Llc | 2024-12-31 | 1.6 M | |
| Polar Capital Holdings Plc | 2024-12-31 | 1.5 M | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 1.5 M | |
| Woodline Partners Lp | 2024-12-31 | 1.5 M | |
| Siren, L.l.c. | 2024-12-31 | 1.4 M | |
| Orbimed Advisors, Llc | 2024-12-31 | 1.3 M | |
| Fiera Capital Corporation | 2024-12-31 | 1.2 M | |
| Fmr Inc | 2024-12-31 | 11.2 M | |
| Vanguard Group Inc | 2024-12-31 | 7.2 M |
SpringWorks Therapeutics Historical Income Statement
SpringWorks Stock Against Markets
SpringWorks Therapeutics Corporate Management
| Badreddin Edris | Chief Officer | Profile | |
| Mary Smith | Chief Officer | Profile | |
| Kim Diamond | Vice Relations | Profile | |
| James MD | Chief Officer | Profile | |
| Michael Nofi | Chief Officer | Profile | |
| TaiAn Lin | Chief Officer | Profile | |
| Saqib JD | CEO Director | Profile |
Additional Tools for SpringWorks Stock Analysis
When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.